Price
No data yet.
Social Signal Score
Analyst Ratings
5 analystsRevenue
$7.67MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Liam J. Kelly
- Sector
- Healthcare
- Industry
- Medical - Specialties
- Employees
- 154
- Beta
- 1.00
- Country
- BE
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -3.38
Financials
Revenue
$7.67M+22146.4%Net Income
$-32.96MEBITDA
$-17.60MFree Cash Flow
$-17.86MEPS (diluted)
$-0.58Shares Outstanding (diluted)
57.01M+283.2%Operating Expenses
$25.16MCash & Debt
$97.78MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $10.02M | $-90.08M | $-2.36 |
| 2024 | $4.52M | $-59.24M | $-1.81 |
| 2023 | $4.35M | $-43.21M | $-1.55 |
| 2022 | $3.08M | $-31.23M | $-1.21 |
| 2021 | $852.0K | $-27.62M | $-1.16 |
| 2020 | $69.0K | $-12.24M | $-0.68 |
| 2019 | $0.00 | $-8.45M | $-0.39 |
| 2018 | $0.00 | $-9.08M | $-0.43 |
| 2017 | $0.00 | $-10.37M | $-0.50 |
Valuation
NYXHhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
77-54.23%Social Signal Score
Mentions (6)
- Newsseekingalpha.com·18d ago·Positive
…a monopoly on 30% of the OSA market by 2027, pending FDA label extension for Complete Concentric Collapse (CCC) patients, supported by strong clinical trial results. NYXH projects €36 million revenue for 2026, up 260% YoY, with visibility supported by rapid growth in trained surgeons, active accounts, and prior authorizations.
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
…ng the Company's strategic U.S. presence and focus Mont-Saint-Guibert, Belgium – September 28, 2026, 10:30 pm CET / 4:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of Liam Kelly as Chief Executive Officer, effective October 1, 2026, succeeding Olivier Taelman. The appointment reflects Nyxoah'…
View source ↗ - Newsglobenewswire.com·31d ago·Neutral
…FO Company reaffirms full year 2026 financial guidance Mont-Saint-Guibert, Belgium – September 21, 2026, 22:01h CET / 4:01h ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that John Landry, Chief Financial Officer, will step down from his role effective October 2, 2026 to pursue another professional opportunity. Loï…
View source ↗ - Newszacks.com·44d ago·Positive
Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial NYXH initiates its U.S. BREATHE study with the first Genio implant, advancing long-term clinical evidence following FDA approval.
View source ↗ - Newsglobenewswire.com·45d ago·Positive
…h Institute, en tant qu'Investigateur Principal du site Mont-Saint-Guibert, Belgique - 7 septembre 2026, 22h05 CET / 16h05 ET - Nyxoah SA (Euronext Bruxelles/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de technologies médicales qui développe des alternatives thérapeutiques révolutionnaires pour l'Apnée Obstructive du Sommeil (AOS) par neuromodulation, a annoncé aujourd'hui que le premier patient a été implanté dans BREATHE, l'étude post-approbation américaine du système Genio menée…
View source ↗ - Newsglobenewswire.com·45d ago·Positive
Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio ® System
View source ↗
Earnings
Thu, Nov 5(in 13 days)
Consensus estimate $-0.35 per share
Typical surprise -6.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.67 vs $-0.47miss
- Tue, May 12$-0.43 vs $-0.54beat
- Thu, Mar 19$-0.68 vs $-0.65miss
- Thu, Nov 13$-0.74 vs $-0.61miss
- Mon, Aug 18$-0.63 vs $-0.62miss
- Wed, May 14$-0.63 vs $-0.49miss
Estimates and results for NYXH via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in NYXH.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.